DSS
MCID: DNG001
MIFTS: 43

Dengue Shock Syndrome (DSS)

Categories: Infectious diseases

Aliases & Classifications for Dengue Shock Syndrome

MalaCards integrated aliases for Dengue Shock Syndrome:

Name: Dengue Shock Syndrome 12 54 15 71
Dss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050125
UMLS 71 C0376300

Summaries for Dengue Shock Syndrome

Disease Ontology : 12 A dengue disease that involves the most severe form of dengue fever, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom easy bruising, has symptom blood spots, has symptom bleeding gums, and has symptom nosebleeds. It is accompanied by circulatory collapse, involves hypotension, narrow pulse pressure (less than or equal to 20mm Hg), or frank shock. The shock occurs after two to six days of symptoms, followed by collapse, weak pulse, and blueness around the mouth.

MalaCards based summary : Dengue Shock Syndrome, also known as dss, is related to dengue disease and colitis, and has symptoms including easy bruising, blood spots and bleeding gums. An important gene associated with Dengue Shock Syndrome is THBD (Thrombomodulin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and t cells.

Related Diseases for Dengue Shock Syndrome

Diseases related to Dengue Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 612)
# Related Disease Score Top Affiliating Genes
1 dengue disease 32.9 TNF SULT1A3 SENP8 IFT81 CSPG5 CD40LG
2 colitis 32.4 TNF IL6 IL1B HLA-DRB1
3 ulcerative colitis 31.8 TNF IL6 IL1RN IL1B HLA-DRB1
4 diarrhea 30.9 TNF THBD IL6 IL1B CD40LG
5 crohn's disease 30.9 TNF IL6 IL1B HLA-DRB1 CCL2
6 dengue hemorrhagic fever 30.8 VEGFA TNF IL6 HLA-A CMA1 CD40LG
7 proteasome-associated autoinflammatory syndrome 1 30.7 TNF IL6 IL1RN IL1B CCL2
8 inflammatory bowel disease 30.7 VEGFA TNF MICB IL6 IL1RN IL1B
9 perinatal necrotizing enterocolitis 30.6 TNF IL6 IL1B
10 gastritis 30.6 TNF IL6 IL1RN IL1B
11 bacterial sepsis 30.5 TNF IL6 IL1RN IL1B
12 cystitis 30.5 VEGFA TNF IL6 CCL2
13 intestinal obstruction 30.5 VEGFA TNF IL6
14 appendicitis 30.4 TNF IL6 IL1B CCL2
15 aspergillosis 30.4 TNF IL6 IL1RN IL1B CD209
16 acute kidney tubular necrosis 30.4 TNF IL6 CD40LG
17 ileus 30.4 TNF IL6 IL1B CCL2
18 acute pancreatitis 30.4 TNF IL6 IL1RN IL1B
19 dysentery 30.4 TNF IL6 IL1B CD40LG
20 parasitic helminthiasis infectious disease 30.4 TNF IL6 IL1B CD40LG
21 autoimmune disease 30.4 TNF IL6 IL1RN IL1B HLA-DRB1 HLA-A
22 disseminated intravascular coagulation 30.4 TNF THBD SULT1A3 IL6
23 myocarditis 30.4 TNF IL6 IL1B CD40LG CCL2
24 respiratory failure 30.3 TNF THBD IL6 IL1RN IL1B CD40LG
25 obsessive-compulsive disorder 30.3 TNF IL6 IL1B CCL2
26 purpura 30.3 TNF THBD IL6 CD40LG
27 congestive heart failure 30.3 VEGFA TNF IL6 IL1B
28 japanese encephalitis 30.3 TNF CD209 CCL2
29 peritonitis 30.3 TNF IL6 IL1B CMA1 CCL2
30 irritable bowel syndrome 30.2 TNF IL6 IL1B
31 toxic shock syndrome 30.2 TNF IL6 IL1RN IL1B CD40LG
32 exanthem 30.1 VEGFA TNF SENP8 IL6 IL1RN IL1B
33 polyneuropathy 30.1 VEGFA TNF IL6 IL1B CD40LG
34 pulmonary disease, chronic obstructive 30.1 TNF IL6 IL1B CCL2
35 urethritis 30.0 TNF IL6 IL1B CSPG5 CD40LG
36 sickle cell anemia 30.0 TNF IL6 CD40LG
37 bacterial infectious disease 30.0 TNF IL6 IL1RN IL1B CD40LG CCL2
38 chronic kidney disease 29.8 VEGFA TNF THBD IL6 IL1B HLA-A
39 encephalitis 29.7 TNF IL6 IL1B CD40LG CD209 CCL2
40 thrombocytopenia 29.7 TNF THBD IL6 IL1RN IL1B HLA-A
41 multiple sclerosis 29.6 TNF IL6 IL1RN IL1B HLA-DRB1 HLA-A
42 diabetes mellitus 29.1 VEGFA TNF THBD IL6 IL1RN IL1B
43 malaria 28.9 VEGFA TNF THBD SULT1A3 IL6 IL1RN
44 dengue virus 11.8
45 46,xy sex reversal 2 11.6
46 hypertrophic neuropathy of dejerine-sottas 11.6
47 neuropathy, congenital hypomyelinating, 1, autosomal recessive 11.5
48 neuropathy, congenital hypomyelinating, 2 11.4
49 charcot-marie-tooth disease, demyelinating, type 4f 11.2
50 physiological polycythemia 10.7 TNF IL1B

Graphical network of the top 20 diseases related to Dengue Shock Syndrome:



Diseases related to Dengue Shock Syndrome

Symptoms & Phenotypes for Dengue Shock Syndrome

Symptoms:

12
  • easy bruising
  • blood spots
  • bleeding gums
  • nosebleeds

Drugs & Therapeutics for Dengue Shock Syndrome

Drugs for Dengue Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 16)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3 Anti-Allergic Agents Phase 4
4 Histamine Antagonists Phase 4
5 Histamine H1 Antagonists Phase 4
6
Histamine Phosphate Phase 4 51-74-1 65513
7 Dermatologic Agents Phase 4
8 Neurotransmitter Agents Phase 4
9 Pharmaceutical Solutions Phase 3
10
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
11 Antacids Phase 1
12 Anti-Ulcer Agents Phase 1
13 Vaccines Phase 1
14 Adjuvants, Immunologic Phase 1
15 Immunologic Factors Phase 1
16 Gastrointestinal Agents Phase 1

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 The Clinical Efficacy and Safety of a Proprietary Solution Containing Hypertonic Sodium Lactate (Totilac®) Infusion for Resuscitation of Patients With Hemorrhagic Shock Due to Multiple Injuries Completed NCT01433276 Phase 3 Hyperosmolar sodium lactate;Ringer's lactate
4 Phase 1, Placebo-Controlled, Double-Blind, Safety Study of HBV-001 D1 in Healthy Adults Completed NCT00936429 Phase 1
5 Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 Completed NCT00375726 Phase 1
6 Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 Completed NCT00322946 Phase 1
7 Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4Δ30 Dengue Vaccine With Boosting at 4 Versus 6 Months Completed NCT00920517 Phase 1
8 Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2 Completed NCT00094705 Phase 1
9 Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1 Completed NCT00089908 Phase 1
10 A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin® Completed NCT01502358 Phase 1
11 A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31‐7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 Completed NCT00831012 Phase 1
12 A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects Completed NCT01084291 Phase 1
13 A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects Completed NCT01073306 Phase 1
14 Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-200,201, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 Completed NCT00270699 Phase 1
15 Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months Completed NCT00473135 Phase 1
16 A Phase 1 Evaluation of the Safety and Immunogenicity of Five Admixtures of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine, in Healthy Flavivirus-naïve Adult Subjects Completed NCT01072786 Phase 1
17 A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects Completed NCT01436422 Phase 1
18 Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals Completed NCT00458120 Phase 1
19 Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers. Completed NCT00919178 Phase 1
20 Factors Associated With Poor Dengue Outcomes in Malaysia Completed NCT02510690
21 Adult Dengue Platelet Study Completed NCT01030211
22 Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore Completed NCT04048837
23 The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia Completed NCT02510638
24 Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection Recruiting NCT00688389

Search NIH Clinical Center for Dengue Shock Syndrome

Genetic Tests for Dengue Shock Syndrome

Anatomical Context for Dengue Shock Syndrome

MalaCards organs/tissues related to Dengue Shock Syndrome:

40
Endothelial, Liver, T Cells, Monocytes, Kidney, Testes, B Cells

Publications for Dengue Shock Syndrome

Articles related to Dengue Shock Syndrome:

(show top 50) (show all 1006)
# Title Authors PMID Year
1
Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. 61 54
17006283 2006
2
Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3beta protein. 61 54
15878791 2005
3
Cytokine patterns during dengue shock syndrome. 54 61
14656693 2003
4
The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. 61 54
11858187 2002
5
Multiple dengue virus serotypes resistant transgenic Aedes aegypti fitness evaluated under laboratory conditions. 61
32138589 2020
6
Acute Demyelinating Polyneuropathy in a Child with Dengue Shock Syndrome. 61
32542487 2020
7
Imported dengue serotype 1 outbreak in a non-endemic region, China, 2017: A molecular and seroepidemiological study. 61
32535157 2020
8
Phylogenetic and recombinant analyses of complete coding sequences of DENV-1 from field-caught mosquitoes in Thailand. 61
32497574 2020
9
Roles of Macrophage Migration Inhibitory Factor in Dengue Pathogenesis: From Pathogenic Factor to Therapeutic Target. 61
32545679 2020
10
Cost-Effectiveness of Dengue Vaccination in Indonesia: Considering Integrated Programs with Wolbachia-Infected Mosquitos and Health Education. 61
32545688 2020
11
Maternal and Neonatal Outcomes during Dengue Infection Outbreak at a Tertiary National Hospital in Endemic Area of Indonesia. 61
32311872 2020
12
An unusual case of dengue shock syndrome complicated by ilio-femoral deep vein thrombosis; a case report. 61
32398134 2020
13
Establishment of Murine Infection Models with Biological Clones of Dengue Viruses Derived from a Single Clinical Viral Isolate. 61
32451883 2020
14
A Review on the Progress and Prospects of Dengue Drug Discovery Targeting NS5 RNA- Dependent RNA Polymerase. 61
32445444 2020
15
Dengue shock syndrome after percutaneous nephrolithotomy leading to hematuria and renal failure: A rare complication. 61
32549667 2020
16
Acute Liver Failure in a Patient With Dengue Shock Syndrome. 61
32548198 2020
17
Interferon lambda 1 is associated with dengue severity in Thailand. 61
31981768 2020
18
Double-faced implication of CD4+ Foxp3+ regulatory T cells expanded by acute dengue infection via TLR2/MyD88 pathway. 61
32125695 2020
19
Daily Dengue Severity Score to Assess Severe Manifestations. 61
31725549 2020
20
Dengue hemorrhagic fever - A systemic literature review of current perspectives on pathogenesis, prevention and control. 61
32265181 2020
21
A prospective 3 year study of clinical spectrum and outcome of dengue fever in ICU from a tertiary care hospital in North India. 61
32346163 2020
22
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model. 61
31942645 2020
23
Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity. 61
32075300 2020
24
Diabetic patients suffering dengue are at risk for development of dengue shock syndrome/severe dengue: Emphasizing the impacts of co-existing comorbidity(ies) and glycemic control on dengue severity. 61
30146413 2020
25
Acute kidney injury among thai pediatric patients with dengue shock syndrome: A re-estimation. 61
32129229 2020
26
Genetic risk for dengue hemorrhagic fever and dengue fever in multiple ancestries. 61
31901861 2020
27
Dengue fever complicated with acute liver failure: A case report of expanded dengue syndrome and literature review. 61
32231783 2020
28
An Attempt Towards Lab And Clinical Combine Appraised, Including Future Concerns Regarding Dengue Infection. 61
32468769 2020
29
A Coupled Mathematical Model of the Intracellular Replication of Dengue Virus and the Host Cell Immune Response to Infection. 61
32411105 2020
30
Aedes aegypti Immune Response and Its Potential Impact on Dengue Virus Transmission. 61
31738698 2020
31
Mast cell mediators in relation to dengue severity: A systematic review and meta-analysis. 61
31709696 2020
32
Identification of inhibitors of dengue viral replication using replicon cells expressing secretory luciferase. 61
31678478 2019
33
Severe Dengue and Associated Hemophagocytic Lymphohistiocytosis in PICU. 61
31353429 2019
34
Molecular Signatures of Dengue Virus-Specific IL-10/IFN-γ Co-producing CD4 T Cells and Their Association with Dengue Disease. 61
31875555 2019
35
Myocarditis Prevalence in Paediatric Dengue Infection: A Prospective Study in Tertiary Hospital in Yogyakarta, Indonesia. 61
31006000 2019
36
Clinical Course and Management of Dengue in Children Admitted to Hospital: A 5 Years Prospective Cohort Study in Jakarta, Indonesia. 61
31738330 2019
37
Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2. 61
31539771 2019
38
Dengue Virus M Protein Promotes NLRP3 Inflammasome Activation To Induce Vascular Leakage in Mice. 61
31413130 2019
39
De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus. 61
31472473 2019
40
Discovery of a small molecule inhibitor targeting dengue virus NS5 RNA-dependent RNA polymerase. 61
31738758 2019
41
Dengue proteins with their role in pathogenesis, and strategies for developing an effective anti-dengue treatment: A review. 61
31784997 2019
42
Dengue Fever in the Darfur Area, Western Sudan. 61
31625864 2019
43
Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection. 61
31451673 2019
44
Serine protease inhibitor AEBSF reduces dengue virus infection via decreased cholesterol synthesis. 61
31386864 2019
45
Genetic diversity and evolutionary dynamics of dengue isolates from India. 61
31803801 2019
46
Impact of population displacement and forced movements on the transmission and outbreaks of Aedes-borne viral diseases: Dengue as a model. 61
31226251 2019
47
The Association between Obesity and Severity of Dengue Hemorrhagic Fever in Children at Wangaya General Hospital. 61
31666844 2019
48
Dengue vaccine development: Global and Indian scenarios. 61
30684747 2019
49
[Travel Related Fever and Rash: Two Cases of Dengue Fever]. 61
31414637 2019
50
Association of ABO blood groups with dengue fever and its complications in a tertiary care hospital. 61
31579269 2019

Variations for Dengue Shock Syndrome

Expression for Dengue Shock Syndrome

Search GEO for disease gene expression data for Dengue Shock Syndrome.

Pathways for Dengue Shock Syndrome

Pathways related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 VEGFA TNF MICB IL6 IL1RN IL1B
2
Show member pathways
13.3 VEGFA TNF IL6 IL1RN IL1B HLA-DRB1
3
Show member pathways
12.9 VEGFA TNF MICB IL6 IL1B HLA-A
4
Show member pathways
12.8 VEGFA TNF IL6 IL1B HLA-DRB1 HLA-A
5 12.75 TNF IL6 IL1B HLA-DRB1 HLA-A CCL2
6
Show member pathways
12.71 TPSAB1 TNF IL6 IL1B HLA-DRB1 HLA-A
7 12.55 TNF IL1RN IL1B CD40LG CCL2
8 12.32 TNF IL6 HLA-DRB1 HLA-A
9
Show member pathways
12.31 TNF IL6 IL1B CCL2
10
Show member pathways
12.3 TNF IL6 IL1B CCL2
11
Show member pathways
12.24 TNF IL1B HLA-DRB1 CD40LG
12 12.22 TNF IL6 IL1B CCL2
13 12.2 TNF IL6 IL1B HLA-DRB1 CD209
14
Show member pathways
12.19 TNF IL6 IL1B CD209
15 12.13 VEGFA TNF IL6 IL1RN IL1B
16 12.04 VEGFA TNF THBD IL1B CCL2
17 11.99 TNF IL6 IL1B CCL2
18 11.99 TNF IL6 IL1B CCL2
19 11.94 TNF IL6 IL1B CCL2
20 11.93 VEGFA TNF IL6 IL1B CCL2
21 11.87 TNF IL6 IL1B HLA-DRB1
22 11.74 TNF IL6 IL1B
23 11.7 TNF THBD IL6 IL1B CD209
24 11.59 TNF IL6 IL1B
25
Show member pathways
11.57 VEGFA TNF IL6 IL1B CD40LG
26 11.52 TNF IL6 IL1B CMA1 CCL2
27 11.51 TNF IL1B CCL2
28 11.48 TNF IL6 IL1B
29 11.4 VEGFA TNF IL6 IL1B HLA-DRB1 CCL2
30 11.38 TNF IL6 IL1B
31 11.35 TNF IL6 IL1B
32 11.35 TNF IL6 IL1B CD40LG CCL2
33 11.33 THBD IL6 CCL2
34 11.3 TNF IL6 IL1B
35 11.27 TNF IL6 IL1B
36 11.24 TNF IL6 IL1RN IL1B CCL2
37 11.22 TNF IL6 IL1B HLA-DRB1
38 11.17 VEGFA TNF THBD PLCE1 IL6 IL1B
39 11.01 TNF PLCE1 IL6 IL1B CD40LG CCL2
40 10.95 TNF IL1B CCL2

GO Terms for Dengue Shock Syndrome

Cellular components related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10 VEGFA TPSAB1 TNF IL6 IL1RN IL1B
2 external side of plasma membrane GO:0009897 9.63 TNF THBD MICB HLA-DRB1 CD40LG CD209
3 cell surface GO:0009986 9.61 VEGFA TNF THBD MICB HLA-DRB1 HLA-A
4 extracellular space GO:0005615 9.44 VEGFA TPSAB1 TNF THBD MICB IL6

Biological processes related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 VEGFA PLCE1 IL6 IL1RN IL1B HLA-DRB1
2 positive regulation of protein phosphorylation GO:0001934 9.91 VEGFA TNF IL1B HLA-DRB1
3 cellular response to lipopolysaccharide GO:0071222 9.89 TNF IL6 IL1B CCL2
4 cytoskeleton organization GO:0007010 9.88 PLCE1 HLA-DRB1 CSPG5 CCL2
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF IL6 IL1B CD40LG
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 VEGFA TNF IL6
7 cellular response to organic cyclic compound GO:0071407 9.81 TNF IL1B CCL2
8 response to glucocorticoid GO:0051384 9.8 TNF IL6 IL1RN
9 inflammatory response GO:0006954 9.8 TNF IL6 IL1RN IL1B CD40LG CCL2
10 humoral immune response GO:0006959 9.79 TNF IL6 CCL2
11 positive regulation of interleukin-6 production GO:0032755 9.77 TNF IL6 IL1B
12 positive regulation of interferon-gamma production GO:0032729 9.71 TNF IL1B HLA-A
13 antigen processing and presentation GO:0019882 9.7 HLA-DRB1 HLA-A CD209
14 protein kinase B signaling GO:0043491 9.67 TNF IL1B CCL2
15 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 TNF IL1B CCL2
16 negative regulation of lipid storage GO:0010888 9.64 TNF IL6
17 regulation of establishment of endothelial barrier GO:1903140 9.62 TNF IL1B
18 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.62 IL6 IL1RN
19 negative regulation of neurogenesis GO:0050768 9.61 TNF IL6 IL1B
20 inflammatory response to antigenic stimulus GO:0002437 9.58 IL1RN IL1B HLA-DRB1
21 regulation of immunoglobulin secretion GO:0051023 9.57 TNF CD40LG
22 positive regulation of fever generation GO:0031622 9.56 TNF IL1B
23 positive regulation of T cell proliferation GO:0042102 9.56 IL6 IL1B CD40LG CD209
24 positive regulation of glial cell proliferation GO:0060252 9.54 TNF IL6 IL1B
25 sequestering of triglyceride GO:0030730 9.51 TNF IL1B
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 TNF IL1B
27 cytokine-mediated signaling pathway GO:0019221 9.43 VEGFA TNF IL6 IL1RN IL1B CCL2
28 positive regulation of neuroinflammatory response GO:0150078 9.33 TNF IL6 IL1B
29 immune response GO:0006955 9.28 TNF MICB IL6 IL1RN IL1B HLA-DRB1

Molecular functions related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 VEGFA TNF IL6 IL1RN IL1B CD40LG
2 peptide antigen binding GO:0042605 9.13 HLA-DRB1 HLA-A CD209

Sources for Dengue Shock Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....